Insider Selling: CryoPort, Inc. (NASDAQ:CYRX) CEO Sells 119,281 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 119,281 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $6.81, for a total value of $812,303.61. Following the completion of the sale, the chief executive officer now owns 912,419 shares in the company, valued at approximately $6,213,573.39. This represents a 11.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Tuesday, June 17th, Jerrell Shelton sold 151,304 shares of CryoPort stock. The shares were sold at an average price of $6.81, for a total value of $1,030,380.24.
• On Friday, June 20th, Jerrell Shelton sold 69,135 shares of CryoPort stock. The shares were sold at an average price of $6.47, for a total value of $447,303.45.
• On Monday, March 24th, Jerrell Shelton sold 2,980 shares of CryoPort stock. The shares were sold at an average price of $6.94, for a total value of $20,681.20.

CryoPort Price Performance

NASDAQ:CYRX traded down $0.41 during midday trading on Friday, hitting $6.37. 607,870 shares of the stock were exchanged, compared to its average volume of 532,638. CryoPort, Inc. has a one year low of $4.58 and a one year high of $9.93. The company has a market capitalization of $319.39 million, a price-to-earnings ratio of -2.72 and a beta of 1.85. The business has a 50-day moving average price of $6.19 and a two-hundred day moving average price of $6.72. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. Sell-side analysts predict that CryoPort, Inc. will post -0.99 EPS for the current year.

Hedge Funds Weigh In On CryoPort

Several institutional investors and hedge funds have recently modified their holdings of CYRX. Rhumbline Advisers grew its holdings in shares of CryoPort by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after acquiring an additional 1,764 shares in the last quarter. Olympiad Research LP acquired a new stake in shares of CryoPort in the 4th quarter valued at $103,000. Heritage Investors Management Corp acquired a new stake in shares of CryoPort in the 4th quarter valued at $122,000. AlphaQuest LLC lifted its stake in shares of CryoPort by 81.3% in the 4th quarter. AlphaQuest LLC now owns 52,714 shares of the company's stock valued at $410,000 after purchasing an additional 23,631 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of CryoPort in the 4th quarter valued at $299,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on CYRX. Morgan Stanley cut their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. Guggenheim restated a "buy" rating and set a $10.00 target price on shares of CryoPort in a research note on Wednesday, April 16th. UBS Group raised their target price on CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, Roth Mkm restated a "buy" rating and set a $15.00 target price on shares of CryoPort in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, CryoPort has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.